



Janine Quinter

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Janine Quinter
St. Gallen

T +41 71 494 1099
Janine.Quinter@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Publications (0)

No results found.

Projects (43)

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Clinical Studies - Aug 16, 2024 - Dec 31, 2099

Ongoing

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS \geq 50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)

Clinical Studies - Aug 13, 2024 - Dec 31, 2028

Ongoing

DS1062-A-U303 (TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS $<$ 50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07

Clinical Studies - May 14, 2024 - Dec 31, 2028

Ongoing

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

Clinical Studies - Apr 18, 2024 - Dec 31, 2028

Completed

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Clinical Studies - Mar 25, 2024 - Dec 31, 2028

Ongoing

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Clinical Studies - Jan 26, 2024 - Dec 31, 2027

Ongoing

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.

Clinical Studies - Dec 21, 2023 - Dec 31, 2027

Ongoing

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Clinical Studies - Nov 17, 2023 - Dec 31, 2028

Ongoing

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Clinical Studies - Nov 3, 2023 - Dec 1, 2028

Ongoing

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Clinical Studies - Oct 30, 2023 - Dec 31, 2026

Ongoing

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Clinical Studies - Oct 18, 2023 - Dec 31, 2028

Ongoing

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)

Clinical Studies - Jul 17, 2023 - Dec 31, 2025

Ongoing

Studie zur Untersuchung, wie gut die Behandlung mit dem Antikörper-Konjugat Sacituzumab Govitecan wirkt bei Frauen mit frühem, HER2-negativem Brustkrebs und ho-hem Rückfallrisiko nach einer medikamentösen Vorbehandlung und Operation im Vergleich zu schon bekannten Therapien

Clinical Studies - Apr 26, 2023 - Dec 31, 2026

Ongoing

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Clinical Studies - Mar 14, 2023 - Dec 31, 2030

Ongoing

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XLO92 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Clinical Studies - Feb 7, 2023 - Dec 31, 2026

Ongoing

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Clinical Studies - Feb 1, 2023 - Dec 31, 2028

Ongoing

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors

Clinical Studies - Jan 11, 2023 - Dec 31, 2028

Ongoing

CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study

Clinical Studies - Dec 9, 2022 - Dec 31, 2027

Ongoing

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer

Clinical Studies - Nov 30, 2022 - Dec 31, 2026

Ongoing

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Clinical Studies - Nov 28, 2022 - Dec 31, 2026

Completed

IP-001_RFA (IP-IIO-622): Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients

Clinical Studies - Nov 8, 2022 - Dec 31, 2024

Completed

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Clinical Studies - Sep 16, 2022 - Dec 31, 2032

Ongoing

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1

Clinical Studies - Sep 9, 2022 - Dec 31, 2026

Completed

CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS

Clinical Studies - Sep 2, 2022 - Sep 8, 2030

Completed

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Clinical Studies - Aug 9, 2022 - Dec 31, 2027

Ongoing

A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Clinical Studies - Jul 8, 2022 - Aug 13, 2024

Automatically Closed

ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)

Clinical Studies - Mar 3, 2022 - Mar 2, 2024

Automatically Closed

A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Clinical Studies - Mar 1, 2022 - Jul 26, 2030

Ongoing

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Clinical Studies - Jan 13, 2022 - Mar 2, 2027

Ongoing

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Clinical Studies - Oct 13, 2021 - Jul 26, 2028

Completed

SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase II trial

Clinical Studies - Jun 24, 2021 - Jun 28, 2027

Ongoing

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial

Clinical Studies - Jun 8, 2021 - Dec 31, 2030

Completed

ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib

Clinical Studies - Apr 14, 2021 - Dec 31, 2025

Completed

MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Clinical Studies - Mar 17, 2021 - May 7, 2030

Ongoing

A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, IIa, Or Select IIIb Non-Small Cell Lung Cancer

Clinical Studies - Feb 12, 2021 - Jul 24, 2024

Aborted

Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients

Clinical Studies - Oct 7, 2020 - Dec 31, 2024

Ongoing

Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial

Clinical Studies - Aug 11, 2020 - Dec 31, 2024

Ongoing

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Clinical Studies - Dec 18, 2019 - Jan 31, 2027

Ongoing

ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma

Clinical Studies - May 2, 2019 - Dec 31, 2024

Ongoing

TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.

Clinical Studies - Oct 26, 2018 - Dec 31, 2026

Ongoing

SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

Clinical Studies - Jun 3, 2016 - May 31, 2026

Ongoing

A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

Clinical Studies - Oct 26, 2015 - Dec 31, 2030

Ongoing

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Clinical Studies - Jul 7, 2014 - Dec 31, 2026

Ongoing